» Articles » PMID: 35326490

Interconnection Between Cardiac Cachexia and Heart Failure-Protective Role of Cardiac Obesity

Overview
Journal Cells
Publisher MDPI
Date 2022 Mar 25
PMID 35326490
Authors
Affiliations
Soon will be listed here.
Abstract

Cachexia may be caused by congestive heart failure, and it is then called cardiac cachexia, which leads to increased morbidity and mortality. Cardiac cachexia also worsens skeletal muscle degradation. Cardiac cachexia is the loss of edema-free muscle mass with or without affecting fat tissue. It is mainly caused by a loss of balance between protein synthesis and degradation, or it may result from intestinal malabsorption. The loss of balance in protein synthesis and degradation may be the consequence of altered endocrine mediators such as insulin, insulin-like growth factor 1, leptin, ghrelin, melanocortin, growth hormone and neuropeptide Y. In contrast to many other health problems, fat accumulation in the heart is protective in this condition. Fat in the heart can be divided into epicardial, myocardial and cardiac steatosis. In this review, we describe and discuss these topics, pointing out the interconnection between heart failure and cardiac cachexia and the protective role of cardiac obesity. We also set the basis for possible screening methods that may allow for a timely diagnosis of cardiac cachexia, since there is still no cure for this condition. Several therapeutic procedures are discussed including exercise, nutritional proposals, myostatin antibodies, ghrelin, anabolic steroids, anti-inflammatory substances, beta-adrenergic agonists, medroxyprogesterone acetate, megestrol acetate, cannabinoids, statins, thalidomide, proteasome inhibitors and pentoxifylline. However, to this date, there is no cure for cachexia.

Citing Articles

Non-Pharmacological Therapy in Heart Failure and Management of Heart Failure in Special Populations-A Review.

Dugal J, Malhi A, Ramazani N, Yee B, DiCaro M, Lei K J Clin Med. 2024; 13(22).

PMID: 39598137 PMC: 11594731. DOI: 10.3390/jcm13226993.


Nutritional and Nutraceutical Support to the Failing Myocardium: A Possible Way of Potentiating the Current Treatment of Heart Failure.

Macri R, Mollace R, Serra M, Scarano F, Ritorto G, Ussia S Int J Mol Sci. 2024; 25(22).

PMID: 39596298 PMC: 11594499. DOI: 10.3390/ijms252212232.


The Prevalence of Coronary Artery Disease and Its Prognostic Impact on the Management of Patients With Acute Decompensated Heart Failure: A Prospective Cohort Study With a Short-Term Follow-Up.

Alnutaifi R, Elshaer F, Alnefaie G, Abozaid T, Alharbi G, Altwaim M Cureus. 2024; 16(10):e71717.

PMID: 39552971 PMC: 11568830. DOI: 10.7759/cureus.71717.


Pathophysiology of Congestion in Heart Failure: A Contemporary Review.

Kumric M, Kurir T, Bozic J, Slujo A, Glavas D, Miric D Card Fail Rev. 2024; 10:e13.

PMID: 39450149 PMC: 11499970. DOI: 10.15420/cfr.2024.07.


Targeting MuRF1 to Combat Skeletal Muscle Wasting in Cardiac Cachexia: Mechanisms and Therapeutic Prospects.

Liu X, Wen Y, Lu Y Med Sci Monit. 2024; 30:e945211.

PMID: 39434377 PMC: 11512513. DOI: 10.12659/MSM.945211.


References
1.
Bays H, Dujovne C . Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep. 2006; 8(2):144-56. DOI: 10.1007/s11883-006-0052-6. View

2.
Kang M, Moon J, Lee J, Kim J, Jung E, Kim S . Metformin induces muscle atrophy by transcriptional regulation of myostatin via HDAC6 and FoxO3a. J Cachexia Sarcopenia Muscle. 2021; 13(1):605-620. PMC: 8818615. DOI: 10.1002/jcsm.12833. View

3.
SCHREIBER S, Evans C, ORATZ M, Rothschild M . Protein synthesis and degradation in cardiac stress. Circ Res. 1981; 48(5):601-11. DOI: 10.1161/01.res.48.5.601. View

4.
Morley J, Thomas D, Wilson M . Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83(4):735-43. DOI: 10.1093/ajcn/83.4.735. View

5.
Singer P, Reintam Blaser A, Berger M, Alhazzani W, Calder P, Casaer M . ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2018; 38(1):48-79. DOI: 10.1016/j.clnu.2018.08.037. View